SS-31 30 mg peptide pen
The mitochondria-targeted tetrapeptide at thirty milligrams, a compound whose clinical trials missed their endpoints, sold by a page that tells you so.
- ISO-certified laboratory
- COA per batch, ≥99% HPLC
- Discreet dispatch within 24 h
- Research use only
Targeted chemistry, mixed results
SS-31 (elamipretide) concentrates in the inner mitochondrial membrane and binds cardiolipin, genuinely elegant targeting that made it one of the field’s most watched compounds. Its clinical programmes then missed primary endpoints in several indications, a fact our compound page reports rather than launders; the trials themselves are listed under elamipretide on ClinicalTrials.gov.
Research interest survives because the mechanism remains real and subgroup signals keep the question open. That is a defensible reason to stock it; it is not a success story, and this page will not dress it as one.
| Compound | SS-31 / elamipretide |
| Content | 30 mg, pre-filled |
| Target | Cardiolipin, inner membrane |
| Purity | ≥ 99% (HPLC) |
| Clinical history | Endpoints missed in key trials |
| Storage | Refrigerate; never freeze |
| Category | Research use only |
A rare case where the honest evidence section subtracts from the sales pitch, read it anyway.
Before the SS-31 30 mg peptide pen reaches the bench
Nothing unusual: the standard pen regimen protects this one too.
Thirty milligrams, run consistently
Why a thirty-milligram series lives on consistent amounts, session after session.
Mechanistic work on SS-31 rarely turns on a single exposure; cardiolipin binding is studied over repeated sessions, and the thirty-milligram pen is sized for that run. Because a targeted tetrapeptide is meant to concentrate in one place, consistent amount is not a nicety, a series that wobbles in quantity blurs whether an effect tracks the molecule or the method. Fixed clicks give each session the same step, the control a targeting hypothesis needs to be tested cleanly.
The mechanics reward that discipline. Each session advances one click and takes a new needle, recorded beside the lot number so every reading traces to this batch of elamipretide. Store the pen refrigerated and clear of the freezer between sessions; a targeted tetrapeptide gains nothing from the freeze-thaw stress the stability page describes. For a compound whose record is already contested, tight handling is the least a researcher controls, it cannot rescue a weak hypothesis, but it stops a skeptic blaming the method.
What it shows, and what it does not
The evidence read straight: real mechanism, missed endpoints, an open question.
Honesty about SS-31 starts with the trials. Its clinical programmes missed their primary endpoints across several indications, a result the compound page states rather than buries. That is not the same as the molecule doing nothing: the cardiolipin targeting is real, and subgroup signals kept enough of the question open that research did not stop. The literature supports a plausible mechanism with poor top-line outcomes; it does not support any claim that the misses were a technicality. Weighing that record before a purchase is exactly the exercise the page on evidence quality asks for.
For a researcher, that record is the specification, not a deterrent to argue away. Anyone weighing whether to buy ss-31 pen stock should read the evidence section as the real product description: a thirty-milligram cartridge whose story is genuinely mixed. Stocking it is not endorsing it, the mechanism justifies study, and that material deserves the same certificate as anything cleaner on the shelf. Sold as research material with nothing promised, it fits a question that remains open.
Mitochondria, three ways
The encoded peptide and the coenzyme that complete this research corner.
The science behind SS-31
The full account, misses included.
Questions about the SS-31 30 mg peptide pen
Straight answers for a complicated record.